Investor Presentation

105 Investor presentation First six months of 2022 Growth momentum has increased driven by demographics and utilisation of full product portfolio International Operations is diverse and covers 190 markets 14% >487m live with diabetes 10% >550m live with obesity IO's share of revenue FY 2021 NAO 48% ΙΟ 52% 6% 5% 2% Historic growth has been in the range of 4-8% Novo NordiskⓇ Growth momentum has benefitted from the Market Fit approach 14% 30% 20% 10% 0% May 2014 2021 2019 Growth rate range NAO: North America Operations; IO: International Operations; Share of Growth not depicted due to high numbers; FY: Full Year NN Diabetes market share Market growth NN Diabetes growth 26% 22% 13% May 2022

View entire presentation